RecruitingPhase 2NCT06440525
A Study of RSLV-132 in Females With Sjögren's Disease
Studying Primary Sjögren disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Resolve Therapeutics
- Principal Investigator
- James PosadaResolve Therapeutics LLC
- Intervention
- RSLV-132(drug)
- Enrollment
- 106 target
- Eligibility
- 18-75 years · FEMALE
- Timeline
- 2024 – 2027
Study locations (24)
- Resolve Clinical Site, Chula Vista, California, United States
- Resolve Clinical Site, Tustin, California, United States
- Resolve Clinical Site, Boca Raton, Florida, United States
- Resolve Clinical Site, Boynton Beach, Florida, United States
- Evolution Research Center, Hialeah, Florida, United States
- GNP Research, Hollywood, Florida, United States
- Resolve Clinical Site, Miami, Florida, United States
- Life Medical Research, Miami Gardens, Florida, United States
- Resolve Clinical Site, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Tufts College, Boston, Massachusetts, United States
- Resolve Clinical Site, Albuquerque, New Mexico, United States
- Joint and Muscle Research Institute, Charlotte, North Carolina, United States
- Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States
- Onsite Clinical Solutions, Salisbury, North Carolina, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06440525 on ClinicalTrials.govOther trials for Primary Sjögren disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07118241A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASELubris Bio Pty Ltd
- RECRUITINGNANCT07324733Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET ImagingPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGNANCT06877546Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's SyndromeKoite Health Oy
- ENROLLING BY INVITATIONNCT06879444"Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's"Pamukkale University
- RECRUITINGPHASE3NCT06684847A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndromeargenx
- ENROLLING BY INVITATIONPHASE2NCT06519617Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular DamageQingwen Tao
- RECRUITINGNCT06528197Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western MedicineChina-Japan Friendship Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT06931041Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical TrialInstituto de Oftalmología Fundación Conde de Valenciana